New Sales Forecast: The Commercial Potential Of HIV.
By Michael Haydock, Lead Analyst
28 January 2016
I am the Lead Analyst of the immunology and inflammation and infectious diseases and vaccines teams at Datamonitor Healt...
Read full bio
Datamonitor Healthcare’s latest 10-year patient-based sales forecast measures the commercial potential of HIV across the US and five major EU markets*. The forecast predicts that sales of HIV therapies will rise from $15.5bn in 2015 to $22.6 bn in 2024 due to the increasing prevalence of infection and launches of novel regimens.
Our analysis of the market dynamics and key therapies on the market and in the pipeline, will enable you to successfully position your product in the HIV market and ensure your company is ahead of the competition.
Our sample extract highlights:
- Physician opinions (from 2015 primary research) of how the availability of generic components will affect prescription of branded FDCs and STRs
- Key price and dose assumptions and sales by country in Datamonitor Healthcare’s forecast of fostemsavir (ViiV Healthcare) for HIV
Explore our forecast on HIV by downloading your exclusive extract from this market leading report >>
If you’re already a subscriber to Datamonitor Healthcare, click here to access the full report.